Abstract
Twenty-five patients with liver metastases, chiefly due to colorectal cancer, were given a loading dose of razoxane for 3 days before 5 consecutive days of radiotherapy to the whole liver. Patients also took razoxane during the radiotherapy and then for one month afterwards. Liver tumour volume was measured on CT scans using the ELSCINT 3D soft tissue imaging programme just before and 4 weeks after the end of radiotherapy treatment. Twelve of the 25 patients had tumour volume reductions of more than 50%. The overall major response rate therefore is 12/25 (48%). In two of the major responders the liver metastases were due to recurrent stomach cancer. In addition to the 12 responders, four patients had a reduction of more than 20% but less than 50%, thus giving an overall response rate of 16/25 (64%). These results can form the basis of a formal, randomized, controlled clinical trial of radiotherapy alone (or any other treatment) compared with radiotherapy and razoxane in the difficult and life threatening condition presented by liver metastases.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bakowski M. T., Macdonald E., Mould R. F., Cawte P., Sloggem J., Barrett A., Dalley V., Newton K. A., Westbury G., James S. E. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):115–119. doi: 10.1016/0360-3016(78)90125-6. [DOI] [PubMed] [Google Scholar]
- Belloni C., Mangioni C., Bortolozzi G., Carinelli S., D'Incalci M., Maggioni A., Morasca L. ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study. Oncology. 1983;40(3):181–185. doi: 10.1159/000225721. [DOI] [PubMed] [Google Scholar]
- Hellmann K., Murkin G. E. Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors. Cancer. 1974 Oct;34(4):1033–1039. doi: 10.1002/1097-0142(197410)34:4<1033::aid-cncr2820340412>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
- Kinsella T. J. The role of radiation therapy alone and combined with infusion chemotherapy for treating liver metastases. Semin Oncol. 1983 Jun;10(2):215–222. [PubMed] [Google Scholar]
- Leibel S. A., Pajak T. F., Massullo V., Order S. E., Komaki R. U., Chang C. H., Wasserman T. H., Phillips T. L., Lipshutz J., Durbin L. M. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1057–1064. doi: 10.1016/0360-3016(87)90045-9. [DOI] [PubMed] [Google Scholar]
- Rhomberg W. U. Radiotherapy combined with ICRF 159 (NSC 129943). Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):121–126. doi: 10.1016/0360-3016(78)90126-8. [DOI] [PubMed] [Google Scholar]
- Rhomberg W., Eiter H. Radioonkologische Behandlungschancen beim Lokalrezidiv des Rektumkarzinoms. Ein interdisziplinärer Vergleich. Wien Med Wochenschr. 1990 Apr 30;140(8):206–211. [PubMed] [Google Scholar]
- Ryall R. D., Hanham I. W., Newton K. A., Hellmann K., Brinkley D. M., Hjertaas O. K. Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159. Cancer. 1974 Oct;34(4):1040–1045. doi: 10.1002/1097-0142(197410)34:4<1040::aid-cncr2820340413>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
- Sharpe H. B., Field E. O., Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. doi: 10.1038/226524a0. [DOI] [PubMed] [Google Scholar]
- Taylor I. W., Bleehen N. M. Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line. Br J Cancer. 1977 May;35(5):587–594. doi: 10.1038/bjc.1977.92. [DOI] [PMC free article] [PubMed] [Google Scholar]